Roger Adsett
Known title: Chief Operating OfficerCIK: 0001685904
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
Transaction History
| INSM | ▲ Buy | Option Exercise | 82,280 | $1.1M | 8/10/2026 | View on chart |
| INSM | ▲ Buy | Option Exercise | 76,600 | $1.3M | 8/10/2026 | View on chart |
| INSM | ▲ Buy | Option Exercise | 80,970 | $2.5M | 8/10/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 239,850 | $32.0M | 8/10/2026 | View on chart |
| DFTX | ▲ Buy | Grant | 3,555 | $0 | 6/11/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 2,370 | $242K | 6/3/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 5,837 | $678K | 5/13/2026 | View on chart |
| INSM | ▲ Buy | Option Exercise | 88,060 | $1.3M | 4/1/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 6,715 | $1.1M | 4/1/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 19,001 | $3.1M | 4/1/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 62,344 | $10.3M | 4/1/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 791 | $124K | 2/3/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 2,059 | $359K | 1/8/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 802 | $140K | 1/7/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 1,429 | $248K | 1/6/2026 | View on chart |
| INSM | ▲ Buy | Grant | 5,998 | — | 1/2/2026 | View on chart |
| INSM | ▼ Sell | Open Market | 20,193 | $2.6M | 8/19/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 4,807 | $617K | 8/19/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 4,186 | $416K | 6/16/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 6,500 | $640K | 6/16/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 1,860 | $133K | 6/3/2025 | View on chart |
| INSM | ▲ Buy | Grant | 6,508 | $0 | 5/15/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 1,925 | $126K | 5/14/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 7,482 | $507K | 5/13/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 5,781 | $453K | 2/10/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 26,141 | $2.1M | 2/10/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 11,053 | $851K | 2/10/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 100 | $8K | 2/7/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 45,605 | $3.7M | 2/6/2025 | View on chart |
| INSM | ▲ Buy | Grant | 88,680 | $0 | 2/5/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 1,457 | $100K | 1/14/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 3,604 | $229K | 1/10/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 1,298 | $83K | 1/10/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 1,882 | $124K | 1/8/2025 | View on chart |
| INSM | ▲ Buy | Grant | 6,657 | — | 1/8/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 2,444 | $161K | 1/7/2025 | View on chart |
| INSM | ▼ Sell | Open Market | 5,945 | $149K | 5/17/2024 | View on chart |
| INSM | ▼ Sell | Open Market | 7,857 | $200K | 5/14/2024 | View on chart |
| INSM | ▲ Buy | Grant | 14,518 | — | 5/13/2024 | View on chart |
| INSM | ▼ Sell | Open Market | 5,251 | $150K | 1/12/2024 | View on chart |
| INSM | ▼ Sell | Open Market | 3,536 | $102K | 1/10/2024 | View on chart |
| INSM | ▼ Sell | Open Market | 3,837 | $112K | 1/9/2024 | View on chart |
| INSM | ▼ Sell | Open Market | 3,042 | $89K | 1/5/2024 | View on chart |
| INSM | ▲ Buy | Grant | 12,873 | — | 1/4/2024 | View on chart |
| INSM | ▼ Sell | Open Market | 8,981 | $174K | 6/13/2023 | View on chart |
| INSM | ▼ Sell | Open Market | 2,448 | $44K | 5/17/2023 | View on chart |
| INSM | ▼ Sell | Open Market | 1,521 | $28K | 5/16/2023 | View on chart |
| INSM | ▼ Sell | Open Market | 2,847 | $55K | 5/15/2023 | View on chart |
| INSM | ▲ Buy | Grant | 31,662 | — | 5/11/2023 | View on chart |
| INSM | ▼ Sell | Open Market | 3,194 | $57K | 1/10/2023 | View on chart |
| INSM | ▼ Sell | Open Market | 3,044 | $60K | 1/5/2023 | View on chart |
| INSM | ▲ Buy | Grant | 7,598 | — | 1/5/2023 | View on chart |
| INSM | ▼ Sell | Open Market | 11,855 | $223K | 11/22/2022 | View on chart |
| INSM | ▼ Sell | Open Market | 2,022 | $41K | 5/17/2022 | View on chart |
| INSM | ▼ Sell | Open Market | 1,394 | $26K | 5/16/2022 | View on chart |
| INSM | ▲ Buy | Grant | 27,460 | — | 5/11/2022 | View on chart |
| INSM | ▼ Sell | Open Market | 1,217 | $30K | 1/12/2022 | View on chart |
| INSM | ▲ Buy | Grant | 17,735 | — | 1/6/2022 | View on chart |
| INSM | ▼ Sell | Open Market | 1,759 | $46K | 1/6/2022 | View on chart |
| INSM | ▼ Sell | Open Market | 3,068 | $85K | 1/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026
Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026. Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.